Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05169515 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 1
Development phase
121
Enrollment target
20
Study locations

NCT05169515 is a Phase 1 study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 121 participants, below the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05169515, a Phase 1 study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 1
Development phase
121 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

Conditions Studied

Non-Hodgkin Lymphoma

Interventions

  • DRUG Obinutuzumab
  • DRUG Iberdomide
  • DRUG Golcadomide
  • DRUG SC Mosunetuzumab
  • DRUG IV Glofitamab

Study Locations (20)

Other

  • Soroka - Beersheba
  • Rambam Health Care Campus - Haifa
  • Hadassah University Hospital - Ein Kerem - Jerusalem
  • Center Hospital - Ramat Gan
  • Sourasky Medical Center - Tel Aviv
  • Hospital Universitari Vall d Hebron - Barcelona
  • Clinica Universidad de Navarra-Madrid - Madrid

Emilia-Romagna

  • IRCCS Azienda Ospedaliero Universitaria di Bologna - Bologna
  • IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori" - Meldola

Lombardy

  • ASST Spedali Civili di Brescia - Brescia
  • Irccs Ospedale San Raffaele - Milan

California

  • UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program - San Francisco

Colorado

  • University of Colorado - Aurora

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • The University of Chicago - Chicago

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2022-10-26
Est. Completion 2029-09-15
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05169515

The ClinicalTrials.gov registry entry for NCT05169515 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (19% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.

NCT05169515 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Emilia-Romagna, Lombardy.

Frequently Asked Questions

What is clinical trial NCT05169515 about?

NCT05169515 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma". This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

What is the current status of trial NCT05169515?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2022-10-26. Estimated completion is 2029-09-15.

What conditions does trial NCT05169515 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT05169515?

The interventions under investigation include: Obinutuzumab (DRUG), Iberdomide (DRUG), Golcadomide (DRUG), SC Mosunetuzumab (DRUG), IV Glofitamab (DRUG).

Who is sponsoring clinical trial NCT05169515?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05169515 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.